Product Details

Catalog No.	ATAD00025
INN (International Nonproprietary Name)	Pertuzumab
Purity	>95%

SDS-PAGE image

|	
Concentration	1.74 mg/ml
Formulation	PBS buffer PH7.4
Source	CHO cells
Endotoxin level	Please contact with the lab for this information.
Note	For research use only .

Bioactivity

Description	Pertuzumab (anti-HER2),a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors,impairs the ability of HER2 to bind to other members of the HER family.

Bioactivity

Alternative names	OMNITARG,rhuMAB 2C4

Specificity target name;species	ERBB2/EGFR2/CD340[Homo sapiens]
Activity in vitro	Pertuzumab (anti-HER2) significantly inhibits the HRG-α-stimulated cellular growth of the 11_18 cells. Pertuzumab blocks HRG-α-stimulated phosphorylation of HER3, mitogen-activated protein kinase (MAPK), and Akt. In contrast, pertuzumab fails to block epidermal growth factor (EGF)-stimulated phosphorylation of EGF receptor (EGFR) and MAPK.Immunoprecipitation shows that pertuzumab inhibited HRG-α-stimulated HER2/HER3 heterodimer formation. HRG-α-stimulated HER3 phosphorylation is also observed in the PC-9 cells co-overexpressing EGFR, HER2, and HER3, but the cell growth is neither stimulated by HRG-α nor inhibited by pertuzumab. Pertuzumab binds to ErbB2 near the center of domain II, sterically blocking a binding pocket necessary for receptor dimerization and signaling. Pertuzumab is specific for human ErbB2 and does not bind to rodent ErbB2 (neu) with detectable affinity.
Species	Humanized
Receptor identification	IgG1-kappa

Chemistry

MV	148000.00 Da
CAS	380610-27-5
Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at +4°C short term (1-2 weeks). Store at -20 °C 12 months. Store at -80°C long term.